Cash position: +€6.6m at June 30, 2017 compared to +€9.3m at December 31, 2016.
Half-year net loss of DEINOVE Group (composed of DEINOVE and DEINOBIOTICS) stands at -€3.3m.
The strategic refocusing announced in September 2016 took shape: DEINOBIOTICS was wholly integrated and the Group made significant progress in its various research programs.
The AGIR project aimed at new antibiotics received a €14.6m funding from the 'Investments for the Future' program operated by Bpifrance.
Montpellier, September 28, 2017 (6:30 p.m. CEST) - DEINOVE (Euronext Growth Paris: ALDEI), a biotech company that discovers, develops and produces high value-added compounds from rare bacterial strains, particularly the Deinococcus genus, released its half-year results for 2017. Following the full integration of its subsidiary DEINOBIOTICS on January 5, 2017, DEINOVE is presenting consolidated financial statements for the first time.
The 2017 interim financial report is available bellow in French (an English version will be available soon).
"A year after announcing our strategic move to focus on high value-added activities in the fields of health, nutrition and cosmetics, the results have been extremely positive," announced Emmanuel Petiot, CEO of DEINOVE. "We have finalized our operational and legal reorganization and completed key stages in each of our R&D programs. This was achieved both with our partners and through our proprietary program for the production of innovative carotenoids, which is on track to have the first compounds produced on an industrial-scale and launched on the market next year. In addition, the recent announcement of the 'Investments for the Future' and Bpifrance’s decision to grant €14.6m in funding to our AGIR (Antibiotics against Resistant Infectious Germs) program ratifies the relevance of our antibiotherapy approach.”